Volume 11 - Articles-1400
MEJDS (2021) 11: 28 |
Back to browse issues page
Ethics code: IR.IAU.K.REC.1399.040
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nasirdehghan M, Tahmouresi N, Moghimbeigi A, Taghavi Kojidi H. Comparing the Effects of Metacognitive Therapy and Reality Therapy on Depression, Quality of Life, and HbA1c in Patients with Type 2 Diabetes. MEJDS 2021; 11 :28-28
URL: http://jdisabilstud.org/article-1-2349-en.html
URL: http://jdisabilstud.org/article-1-2349-en.html
1- Department of Psychology, Karaj Branch, Islamic Azad University
2- Department of Biostatistics and Epidemiology, School of Health, Alborz University of Medical Sciences
3- Department of Medicine, Alborz University of Medical Sciences
2- Department of Biostatistics and Epidemiology, School of Health, Alborz University of Medical Sciences
3- Department of Medicine, Alborz University of Medical Sciences
Abstract: (1064 Views)
Background & Objectives: Due to the global prevalence, increasing mortality, and susceptibility of diabetes, as well as its significant biopsychological dimensions, providing medical and psychological treatment to the affected patients, is vital. A highly frequent problem in patients with type 2 diabetes is depression; this condition directly affects the individual’s biopsychological health. Furthermore, its prevalence in patients with type 2 diabetes is 2–3 times higher than the general population. Depression can directly impact the biological characteristics of subjects with diabetes, such as fasting blood glucose and HbA1c. Moreover, it greatly affects the Quality of Life (QoL) and mental health of this group. Inattention and late diagnosis of psychological issues in diabetics can threaten their health; accordingly, comorbid biopsychological and behavioral problems may complicate the disease control. Eventually, it leads to other physical problems associated with diabetes, such as cardiovascular disease, retinopathy, blindness, neuropathy, and so on. Thus, this study aimed to compare the effects of Metacognitive Therapy (MCT) and Reality Therapy (RT) on depression, QoL, and HbA1c in patients with type 2 diabetes.
Methods: This was a quasi–experimental study with a pretest–posttest–follow–up and a control group design. The statistical population included all female patients with type 2 diabetes in Karaj City, Iran, in 2020; They initially completed the Beck Depression Inventory (BDI; Beck, 1996) before entering the experimental setting. Subjects with a depression score of >11 were randomly assigned to the study. In total, 45 eligible volunteers were randomly available as a sample. Then, they were randomly divided into the MCT and RT experimental groups and controls (n=15/group). The inclusion criteria of the study were having a minimum literacy to complete the questionnaires; the age range of 40–60 years; a one–year history of type 2 diabetes, and no abuse of drugs and use of psychotropic drugs. The exclusion criteria also included the presence of severe physical illnesses due to diabetes, such as renal failure, vision, etc.; receiving psychological therapies during the intervention; taking any sedatives or psychiatric drugs; increasing the dose of diabetes–related drugs; absence from >2 intervention sessions and the patient's unwillingness to continue treatment. The MCT and RT groups received eight 90–minute intervention sessions; however, the control group received no intervention. The required data were collected using the BDI–II (Beck et al., 1996), the Quality of Life Questionnaire–SF36 (Weir & Sherborne, 1992), and the HbA1c blood test. In all study groups, a pretest was performed before the intervention and after 8 sessions, the posttest was performed. Finally, one month after the posttest, in the follow–up phase, the mentioned measures were re–performed. For data analysis, descriptive statistics, including mean and standard deviation were used. Moreover, inferential statistics, including repeated–measures Analysis of Variance (ANOVA) and Bonferroni posthoc test were employed in SPSS at p<0.05.
Results: The present research results suggested that by controlling the pretest effects, MCT and RT presented a reducing effect on depression (p<0.001) and an increasing effect on QoL (p=0.012) in the study subjects. There was no significant difference in the posttest and follow–up scores between the MCT and RT groups; this effect remained until the follow–up stage (p>0.05). Concerning HbA1c, MCT and RT provided no significant effect (p=0.661) and were not significant over time (p=0.542). Additionally, there was a significant difference between the MCT and RT groups and the controls (p<0.001). However, there was no significant difference between the MCT and RT groups in this regard (p=1.000).
Conclusion: According to the current research results, MCT and RT were effective in reducing depression and increasing QoL among patients with type 2 diabetes; the therapeutic results of the interventions lasted until the follow–up step.
Methods: This was a quasi–experimental study with a pretest–posttest–follow–up and a control group design. The statistical population included all female patients with type 2 diabetes in Karaj City, Iran, in 2020; They initially completed the Beck Depression Inventory (BDI; Beck, 1996) before entering the experimental setting. Subjects with a depression score of >11 were randomly assigned to the study. In total, 45 eligible volunteers were randomly available as a sample. Then, they were randomly divided into the MCT and RT experimental groups and controls (n=15/group). The inclusion criteria of the study were having a minimum literacy to complete the questionnaires; the age range of 40–60 years; a one–year history of type 2 diabetes, and no abuse of drugs and use of psychotropic drugs. The exclusion criteria also included the presence of severe physical illnesses due to diabetes, such as renal failure, vision, etc.; receiving psychological therapies during the intervention; taking any sedatives or psychiatric drugs; increasing the dose of diabetes–related drugs; absence from >2 intervention sessions and the patient's unwillingness to continue treatment. The MCT and RT groups received eight 90–minute intervention sessions; however, the control group received no intervention. The required data were collected using the BDI–II (Beck et al., 1996), the Quality of Life Questionnaire–SF36 (Weir & Sherborne, 1992), and the HbA1c blood test. In all study groups, a pretest was performed before the intervention and after 8 sessions, the posttest was performed. Finally, one month after the posttest, in the follow–up phase, the mentioned measures were re–performed. For data analysis, descriptive statistics, including mean and standard deviation were used. Moreover, inferential statistics, including repeated–measures Analysis of Variance (ANOVA) and Bonferroni posthoc test were employed in SPSS at p<0.05.
Results: The present research results suggested that by controlling the pretest effects, MCT and RT presented a reducing effect on depression (p<0.001) and an increasing effect on QoL (p=0.012) in the study subjects. There was no significant difference in the posttest and follow–up scores between the MCT and RT groups; this effect remained until the follow–up stage (p>0.05). Concerning HbA1c, MCT and RT provided no significant effect (p=0.661) and were not significant over time (p=0.542). Additionally, there was a significant difference between the MCT and RT groups and the controls (p<0.001). However, there was no significant difference between the MCT and RT groups in this regard (p=1.000).
Conclusion: According to the current research results, MCT and RT were effective in reducing depression and increasing QoL among patients with type 2 diabetes; the therapeutic results of the interventions lasted until the follow–up step.
Keywords: Type 2 diabetes , Depression , Quality of life , Metacognitive therapy , Reality therapy , HbA1c
Type of Study: Original Research Article |
Subject:
Psychology
References
1. 1. Bennich BB, Munch L, Egerod I, Konradsen H, Ladelund S, Knop FK, et al. Patient assessment of family function, glycemic control and quality of life in adult patients with type 2 diabetes and incipient complications. Can J Diabetes. 2019;43(3):193–200. [DOI]
2. 2. Nini Shuhaida MH, Siti Suhaila MY, Azidah KA, Norhayati NM, Nani D, Juliawati M. Depression, anxiety, stress and socio-demographic factors for poor glycaemic control in patients with type II diabetes. J Taibah Univ Med Sci. 2019;14(3):268–76. [DOI]
3. 3. Nicolau J, Simó R, Conchillo C, Sanchís P, Blanco J, Romerosa JM, et al. Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes. J Endocrinol Invest. 2019;42(8):881–8. [DOI]
4. 4. van der Donk LJ, Fleer J, Sanderman R, Emmelkamp PMG, Links TP, Tovote KA, et al. Is type of depressive symptoms associated with patient-perceived need for professional psychological care in depressed individuals with diabetes? PLoS One. 2019;14(2):e0212304. [DOI]
5. 5. Li H, Ji M, Scott P, Dunbar-Jacob JM. The effect of symptom clusters on quality of life among patients with type 2 diabetes. Diabetes Educ. 2019;45(3):287–94. [DOI]
6. 6. Bruno BA, Choi D, Thorpe KE, Yu CH. Relationship among diabetes distress, decisional conflict, quality of life, and patient perception of chronic illness care in a cohort of patients with type 2 diabetes and other comorbidities. Diabetes Care. 2019;42(7):1170–7. [DOI]
7. 7. Danhauer SC, Brenes GA, Levine BJ, Young L, Tindle HA, Addington EL, et al. Variability in sleep disturbance, physical activity and quality of life by level of depressive symptoms in women with Type 2 diabetes. Diabet Med. 2019;36(9):1149–57. [DOI]
8. 8. Shah BM, Mezzio DJ, Ho J, Ip EJ. Association of ABC (HbA1c, blood pressure, LDL-cholesterol) goal attainment with depression and health-related quality of life among adults with type 2 diabetes. J Diabetes Complications. 2015;29(6):794–800. [DOI]
9. 9. Wells A. Metacognitive therapy for anxiety and depression. Akbari M, Andooz Z, Majidi A. (Persian translator). Tehran: Arjmand Pub; 2015.
10. 10. Ashoori J. The effects of meta-cognitive therapy on generalized anxiety disorder and depression among patients with type II diabetes. Journal of Diabetes Nursing. 2015;3(2):19–29. [Persian] [Article]
11. 11. Glasser W. Reality therapy: a new approach to psychiatry. Sahebi A. (Persian translator). Tehran: Saye Sokhan Pub; 2017, pp: 24–31.
12. 12. Farshchi N, Kiani Q, Chiti H. Effectiveness of group therapy reality in reducing depression, anxiety and increased compliance to treatment in patients with diabetic type 1. Journal of Advances in Medical and Biomedical Research. 2018;26(117):74–85. [Persian] [Article]
13. 13. Delavar A. Research methods in psychology and educational sciences. Tehran: Virayesh Pub; 2007. [Persian]
14. 14. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
15. 15. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988;8(1):77–100. [DOI]
16. 16. Hamidi R, Fekrizadeh Z, Azadbakht M, Garmaroudi G, Taheri Tanjani P, Fathizadeh S, et al. Validity and reliability Beck Depression Inventory-II among the Iranian elderly population. J Sabzevar Uni Med Sci. 2015;22(1):189–98. [Persian] [Article]
17. 17. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.
18. 18. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005;14(3):875–82. [DOI]
19. 19. Hinkle JL, Cheever KH. Brunner LS. Brunner & Suddarth's textbook of medical-surgical nursing. 13th edition. Philadelphia: Lippincott Williams & Wilkins; 2013.
20. 20. Jelinek L, Van Quaquebeke N, Moritz S. Cognitive and metacognitive mechanisms of change in metacognitive training for depression. Scientific Reports. 2017;7(1):3449. [DOI]
21. 21. Normann N, van Emmerik AAP, Morina N. The efficacy of metacognitive therapy for anxiety and depression: a meta-analytic review. Depress Anxiety. 2014;31(5):402–11. [DOI]
22. 22. Solem S, Edward Ottesen Kennair L, Hagen R, Havnen A, Nordahl HM, Wells A, et al. Metacognitive therapy for depression: A 3-year follow-up study assessing recovery, relapse, work force participation, and quality of life. Fronti Psychol. 2019;10:2908. https://doi.org/10.3389/fpsyg.2019.02908
23. 23. Glasser C. A choice theory psychology guide to happiness: how to make yourself happy (the choice theory in action series). Independently Published; 2019.
24. 24. Barzegar Damadi MA, Mirzaian B, Akha O, Hosseini H, Jadidi M. Effect of cognitive-behavioral group therapy on hba1c, self-efficacy, depression, illness perception, and quality of life in patients with type II diabetes. J Mazandaran Uni Med Sci. 2018;27(158):87–100. [Article]
25. 25. van Son J, Nyklícek I, Pop VJ, Blonk MC, Erdtsieck RJ, Spooren PF, et al. The effects of a mindfulness-based intervention on emotional distress, quality of life, and HbA(1c) in outpatients with diabetes (DiaMind): a randomized controlled trial. Diabetes Care. 2013;36(4):823–30. [DOI]
26. 26. van Bastelaar KMP, Pouwer F, Cuijpers P, Riper H, Snoek FJ. Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2011;34(2):320–5. [DOI]
27. 27. Hartmann M, Kopf S, Kircher C, Faude-Lang V, Djuric Z, Augstein F, et al. Sustained effects of a mindfulness-based stress-reduction intervention in type 2 diabetic patients: design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-study). Diabetes Care. 2012;35(5):945–7. [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
